Predictors and outcomes of healthcare-associated infections in COVID-19 patients.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Gagan KumarAchuta Kumar Guddati

Abstract

Healthcare-associated infections (HAI) after viral illnesses are important sources of morbidity and mortality. This has not been extensively studied in hospitalized COVID-19 patients. This study included all COVID-19-positive adult patients (≥18 years) hospitalized between 01 March and 05 August 2020 at the current institution. The Centers for Disease Control and Prevention definition of HAI in the acute care setting was used. The outcomes that were studied were rates and types of infections and in-hospital mortality. Several multivariable logistic regression models were constructed to examine characteristics associated with development of HAI. Fifty-nine (3.7%) of 1565 patients developed 140 separate HAIs from 73 different organisms: 23 were Gram-positive, 39 were Gram-negative and 11 were fungal. Patients who developed HAI did not have higher odds of death (OR 0.85, 95% CI 0.40-1.81, p =  0.69). HAIs were associated with the use of tocilizumab (OR 5.04, 95% CI 2.4-10.6, p <  0.001), steroids (OR 3.8, 95% CI 1.4-10, p =  0.007), hydroxychloroquine (OR 3.0, 95% CI 1.0-8.8, p =  0.05), and acute kidney injury requiring hemodialysis (OR 3.7, 95% CI 1.1-12.8, p =  0.04). HAI were common in hospitalized Covid-19 patients. Tocilizum...Continue Reading

References

Jun 13, 2009·American Journal of Respiratory Cell and Molecular Biology·Lynnelle A PittetAllen G Harmsen
Apr 29, 2011·American Journal of Infection Control·Naomi P O'GradyUNKNOWN Healthcare Infection Control Practices Advisory Committee
Dec 1, 2011·Critical Care : the Official Journal of the Critical Care Forum·Hannah MuskettDavid Harrison
Sep 9, 2015·Therapeutics and Clinical Risk Management·Mohamed A HendausAhmed H Alhammadi
Mar 25, 2016·Nature Reviews. Rheumatology·Alexei A GromFabrizio De Benedetti
Sep 13, 2016·Chest·Shipra GuptaKianoush B Kashani
Apr 14, 2017·The Lancet. Gastroenterology & Hepatology·Bastiaan W Haak, W Joost Wiersinga
Feb 9, 2020·Nature Reviews. Rheumatology·Eva Schrezenmeier, Thomas Dörner
Apr 14, 2020·International Journal of Rheumatic Diseases·Sanket ShahVir Singh Negi
May 8, 2020·The New England Journal of Medicine·Joshua GelerisNeil W Schluger
May 26, 2020·European Journal of Internal Medicine·Valentina MorenaMario Corbellino
Jun 24, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley C JordanEdmund Huang
Jul 11, 2020·JAMA : the Journal of the American Medical Association·W Joost WiersingaHallie C Prescott

❮ Previous
Next ❯

Citations

Mar 16, 2021·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Prachi R PatelAndrea Benin
May 4, 2021·Trends in Microbiology·Lars F WestbladeMichael J Satlin
May 28, 2021·Current Opinion in Infectious Diseases·Madhuri M Sopirala
Sep 3, 2021·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lindsey M Weiner-LastingerMargaret A Dudeck
Sep 25, 2021·Journal of Medical Virology·Gagan KumarAchuta Kumar Guddati

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar
X-ray

Software Mentioned

STATA MC
Epic®

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.